Pyxis Oncology (NASDAQ:PYXS) Earns Buy Rating from Analysts at Stifel Nicolaus

Stifel Nicolaus began coverage on shares of Pyxis Oncology (NASDAQ:PYXS) in a research note issued to investors on Thursday, Marketbeat.com reports. The firm issued a buy rating and a $10.00 price objective on the stock.

Other research analysts have also recently issued reports about the company. Jefferies Financial Group reissued a buy rating and set a $10.00 price objective on shares of Pyxis Oncology in a report on Tuesday, May 7th. HC Wainwright restated a buy rating and issued a $7.00 target price on shares of Pyxis Oncology in a research note on Thursday, May 16th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of Buy and a consensus target price of $9.00.

Pyxis Oncology Price Performance

Shares of NASDAQ:PYXS opened at $3.29 on Thursday. The business’s fifty day moving average price is $3.44 and its two-hundred day moving average price is $4.24. Pyxis Oncology has a fifty-two week low of $1.35 and a fifty-two week high of $6.85. The stock has a market capitalization of $193.75 million, a price-to-earnings ratio of -2.42 and a beta of 1.29.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings data on Saturday, May 11th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.19. The company had revenue of $16.15 million for the quarter, compared to the consensus estimate of $4.25 million. Research analysts expect that Pyxis Oncology will post -1.09 EPS for the current fiscal year.

Institutional Trading of Pyxis Oncology

A number of hedge funds and other institutional investors have recently made changes to their positions in PYXS. Fullcircle Wealth LLC acquired a new stake in Pyxis Oncology in the second quarter worth about $40,000. SG Americas Securities LLC acquired a new stake in Pyxis Oncology in the first quarter worth about $59,000. Cetera Advisors LLC acquired a new stake in Pyxis Oncology in the first quarter worth about $100,000. Schulhoff & Co. Inc. increased its position in Pyxis Oncology by 90.9% in the second quarter. Schulhoff & Co. Inc. now owns 42,000 shares of the company’s stock worth $139,000 after purchasing an additional 20,000 shares during the period. Finally, American Century Companies Inc. increased its position in Pyxis Oncology by 56.0% in the second quarter. American Century Companies Inc. now owns 58,252 shares of the company’s stock worth $193,000 after purchasing an additional 20,901 shares during the period. 39.09% of the stock is currently owned by institutional investors and hedge funds.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.